This is a frequent exam topic, and the relevant curriculum item is probably "the causes, preention and treatment of infections seen in... [the] critically ill".
VAP has appeared twice in the CRQ paper, in 2018 (pass rate 38.6%) and 2023 (30.3%); definition, preventative strategies against VAP and care bundles are all areas where marks have been lost en masse.
Ventilator-associated pneumonia (VAP) is defined as an infection of the pulmonary parenchyma occurring ≥48hrs after the initiation of invasive mechanical ventilation
It can be further sub-classified into early (onset ≤5 days) or late (onset >5 days) VAP
Microbial presence in the lower respiratory tract probably exists as a spectrum: airway colonisation → tracheobronchitis → pneumonia
VAP is associated with increased morbidity and mortality, although it is unclear whether VAP itself causes the poor outcomes
Prevalence of 15 - 20% amongst patients ventilated for ≥48hrs
Incidence of 13.6 per 1,000 ventilator days
Rates vary between regions (higher in Europe than North America), likely reflecting differences in definitions, screening and patient groups
Responsible for a large proportion of antibiotic use on ICU
Attributable mortality is debated, but estimated to be up to 13%
Associated with:
Up to 6 additional days of mechanical ventilation
Up to 10 additional days of ICU stay
An estimated cost of ∽£10,000 per patient in the UK
Risk factors
Patient factors
Hospitalisation and ventilatory factors
Advanced age
Admission with reduced conscious level
Male sex
Burns or trauma
Smoking history
Previous antibiotics, esp. if broad-spectrum
Immunosuppression
Prolonged duration of I&V
Diabetes
Supine position
Existing lung disease
Re-intubation following unsuccessful extubation
The causative organisms tend to relate to the timing between onset of mechanical ventilation and start of VAP
Weighted score based on temperature, white cell count, tracheal secretions, CXR, oxygenation (P/F ratio) and culture of tracheal secretions
A score of >6 suggests a high probability of VAP, but CPIS has poor diagnostic accuracy
HELICS criteria
Used for surveillance across Europe
Requires radiological, systemic and respiratory criteria to all be met
CDC ventilator-associated event criteria
A surveillance tool using electronic health record data; sensitive but lacks specificity for clinically important VAP
Difficulties in diagnosis
Worsening oxygenation and new CXR infiltrates are common in critical illness, and often non-infective
Fluid overload
Atelectasis
Mucus plugging
The respiratory tract is not sterile; a positive culture may represent colonisation rather than infection
An organism isolated in the bloodstream may not be the same one causing the VAP
Lower respiratory tract sampling
Tracheal aspirate
Advantages
Disadvantages
Cheap and easy to perform
Proximal airway colonisation is common; may not represent true infection
Minimally invasive
Risk of unnecessary antibiotic use, promoting MDR flora
Allows Gram stain and culture
Novel tests (quantitative culture, PCR) not well validated on these samples
Bronchoalveolar lavage (BAL) via fibreoptic bronchoscope
Advantages
Disadvantages
With quantitative culture, may better identify true VAP
Invasive
May optimise antibiotic selection and reduce antibiotic exposure
Requires more equipment and personnel
Poorly tolerated in severe hypoxaemia
Non-directed bronchial lavage (blind instillation and aspiration of saline) is a less invasive alternative
Invasive sampling has not been shown to improve patient-centred outcomes compared with minimally invasive techniques
Novel diagnostics
Multiplex PCR
Rapid detection of common VAP pathogens and resistance genes
Only 50 - 60% concordance with culture and cannot distinguish viable from non-viable organisms, so risks over-detection
Volatile organic compounds on HME filters
May detect VAP up to 3 days before clinical signs although currently a research tool only
Prevention strategies aim to reduce VAP incidence, but few have translated into a mortality benefit
Minimise time on ventilator
Reduce risk of aspiration
Optimise microbial ecology
Avoid (re-)intubation
Elevate head of bed 30 - 45°
Selective decontamination of the digestive tract (SDD)
Early extubation/early weaning protocol
Subglottic suction/aspiration
Oral hygiene
Daily sedation breaks and spontaneous breathing trials
Maintain cuff pressure 20 - 30cmH2O
Avoid routine ventilator circuit changes
Ventilator care bundle
The original ventilator bundle was comprised of:
Head of bed elevation to 30°
Daily sedation holds and spontaneous breathing trials
Stress ulcer prophylaxis
VTE prophylaxis
This has since been modified by many societies to include some of the measures in the table above
Bundles are associated with a reduced incidence of VAP, but the evidence comes from small before-and-after observational studies, at high risk of bias
Selective decontamination of the digestive tract
Non-absorbable antimicrobials applied to the oropharynx and GI tract ± a short course of IV antibiotics
The SuDDICU trial found no significant difference in mortality, but an accompanying meta-analysis suggested a high probability of reduced in-hospital mortality and VAP
The effect is greater when an IV antibiotic component is included
Patients at high risk of VAP, e.g. acute brain injury, may benefit most
Concern regarding promotion of MDR organisms so implementation requires local multidisciplinary agreement
Stress ulcer prophylaxis
PPIs raise gastric pH, which was thought to favour bacterial growth and increase VAP risk
Large RCTs comparing PPIs with placebo found no difference in infective complications
Current evidence suggests PPIs for stress ulcer prophylaxis are likely safe and not associated with increased VAP
Gastric residual volume (GRV) monitoring
Not monitoring GRV is non-inferior to routine monitoring with regards to VAP incidence
Routine GRV monitoring is not recommended for VAP prevention although it may still be used to guide feed tolerance
Prophylactic antibiotics
Inhaled amikacin, and short courses of IV antibiotics in patients with brain injury or post-cardiac arrest, have reduced VAP incidence in trials
No consistent mortality benefit has been shown thus this remains an area of ongoing research and is not routine practice
Empirical antibiotics
Choice is guided by risk factors for MDR organisms, the local antibiogram, clinical course and illness severity
Early-onset VAP with no MDR risk factors
Third-generation cephalosporin or co-amoxiclav
Late-onset VAP (>5 days) or MDR risk factors
Broad-spectrum anti-pseudomonal β-lactam, e.g. piperacillin-tazobactam, cefepime or meropenem
Add MRSA cover (vancomycin or linezolid) if at high risk
Narrow the spectrum according to microbiology results as soon as possible
Input from Microbiology regarding antimicrobial selection/organism resistance locally
Drawbacks of anti-pseudomonal agents
Meropenem: widespread use promotes carbapenemase-producing organisms
Piperacillin-tazobactam: may not adequately cover AmpC β-lactamase producers
Cefepime: associated with neurotoxicity (GABA receptor inhibition) and fewer delirium/coma-free days
Continuous infusion of β-lactams
β-lactams exhibit time-dependent killing, i.e. efficacy depends on the time the concentration remains above the MIC
The BLING III trial showed no significant difference in the primary analysis, but adjusted analysis and a subsequent meta-analysis favoured continuous infusion
Continuous infusion is recommended in VAP patients meeting criteria for sepsis or septic shock
Duration
Guidelines recommend 7 - 8 days in patients with a good clinical response
Shorter courses do not increase treatment failure and increase antibiotic-free days
Longer courses may be needed for immunodeficiency, cystic fibrosis, empyema, lung abscess, cavitation or necrotising pneumonia; decided with ID/Microbiology
The REGARD-VAP trial found individualised courses as short as 3 - 5 days were non-inferior to longer courses
Supportive management
Lung-protective ventilation, as these patients are at risk of ARDS
Corticosteroids: little evidence of benefit in VAP (unlike severe CAP)
Otherwise as for any other ICU patient
Effective
Ongoing research
Unclear or no benefit
Selective decontamination of the digestive tract
Prophylactic antibiotics
Gastric residual volume monitoring
Continuous β-lactam infusion
Novel microbiological diagnostics
Avoiding PPIs
Shorter treatment duration
Care bundles
Narrowing the antibiotic spectrum
Corticosteroids
A care bundle is:
A group of evidence-based interventions which, when delivered together, lead to a better clinical outcome than performing interventions individually
A recent review suggests the effect of ICU care bundles on patient outcomes may be inconclusive, except for the sepsis bundles
(BMJ Open, 2023)
Examples
Ventilator care bundle
Central line insertion care bundle
Implementation of a CVC care bundle reduced catheter-related bloodstream infections to 66% of pre-bundle levels
Sepsis six care bundle
Implementation associated with a reduction in mortality of ∽6% over 2yrs